Navigation Links
Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
Date:9/23/2009

NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced results of the Open Label Extension (OLE) trial of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The OLE trial, conducted in Taiwan, enrolled 29 of the 37 Taiwanese patients that had completed the randomized, multi-center, multi-national (United States and Taiwan) dose-ranging Phase 2 study. This OLE represents the first trial to examine the long-term safety and efficacy of Zerenex as a phosphate binder. The treatment period in all previous Zerenex Phase 2 clinical trials did not exceed 28 days.

The OLE trial provided for a daily dose, ranging from 2 to 6 g/day of Zerenex, for a period of up to one year following completion of the 28-day, dose-ranging Phase 2 study. The average duration of the patients' participation in the OLE trial was 306 +/- 85 days.

Data from the OLE trial indicate that the mean serum phosphorus level throughout the trial was 5.22 +/- 0.18 mg/dL, and the mean product of calcium times phosphate (CaxP) was 49.06 +/- 2.15 mg(2)/dL(2), both within the normal range as recommended by the KDOQI guidelines. In addition, during the OLE trial, the administration of IV iron as a supplement was withheld in 8 patients (27.6%) for periods ranging from 3 to 6 months and the administration of EPO was withheld in 8 patients (27.6%) for short periods because the hemoglobin, hematocrit, and iron parameters were within normal clinical ranges as assessed by the investigator. There were no signs of potential iron overload in the study patients, and there were no Zerenex-related serious adverse events as noted by either the pati
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
2. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
10. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  Rebiotix Inc. announced this morning that results of ... RBX2660 (microbiota suspension) will be presented in two posters and ... Philadelphia from October 8-12. ... session on Thursday, October 9, 2014: Poster: RBX2660 ... Interim Analysis of the PUNCH-CD Phase 2 Safety Study ...
(Date:9/17/2014)... 17, 2014  Bayer HealthCare will present data on ... th Annual Meeting, which takes place September 18-20 ... which will be shared through poster presentations, showcase Bayer,s ... Data will be presented in a scientific forum. ... in hemophilia A patients, Bayer is maintaining its commitment ...
(Date:9/17/2014)... September 17, 2014 According to ... Component (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU), by ... Wellness), and by Geography - Global Forecast to 2020", ... market is expected to reach $56.50 Billion by 2020, ... 2020. Browse 235 market data Tables and ...
Breaking Medicine Technology:PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4
... (Nasdaq: ENDP ) today announced that it will present ... 2011 at 3:45 p.m. ET.  Dr. Ivan Gergel executive vice president ... programs. The presentation will be webcast live and can ... investors section.   About Endo ...
... nation,s leading retail pharmacy, brings its "To Your Health" ... Texas. The program will provide free preventive health screenings ... through November as a way to help citizens determine ... a path to better health. (Logo: ...
Cached Medicine Technology:CVS/pharmacy Debuts the 'To Your Health' Program in Dallas and Fort Worth Texas, Bringing More Than 80 Free Health Screening Events to the Community 2CVS/pharmacy Debuts the 'To Your Health' Program in Dallas and Fort Worth Texas, Bringing More Than 80 Free Health Screening Events to the Community 3
(Date:9/18/2014)... 2014 Dentists from throughout Canada ... acclaimed Oxnard All-on-4™ dental implants expert ... from the Anacapa Dental Art Institute in Ventura ... Academy of Restorative Dentistry and Prosthodontics (CARDP) annual ... “Resection Versus Augmentation: Esthetic Implant Supported Maxillary Prostheses,” ...
(Date:9/18/2014)... 2014 Each year, Norman Regional Hospital ... coincide with National Health IT (NHIT) Week to celebrate ... help Norman Regional show its gratitude, Access, the ... is contributing giveaway items to support their NHIT Week ... and offering free lunches, Norman Regional is spending time ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 According to the ... from eczema, with many of them being children. In fact, ... diagnosed as babies and children. The millions of children who ... be brought on by eczema. A new book has been ... they are and to find relief from the condition over ...
(Date:9/18/2014)... Dr. Suzaunna Clark, Psychologist, Life Coach and Licensed ... to be seen to be believed and 2- that ... be used. Together, both lead to hearts that heal. ... do both. , Dr. Clark offers professional ... system, which provides professional guidance on dealing with everyday ...
(Date:9/18/2014)... Mateo, CA (PRWEB) September 18, 2014 ... archiving solutions, from active, to medium, and even long ... of content for any length of time. This includes ... of machine-produced data. When used together, Nautilus and ASG-Digital ... managing archive content. , "storageFOUNDRY is pleased to ...
Breaking Medicine News(10 mins):Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 2Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 3Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 4Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 5Health News:Access Helps Norman Regional Hospital Celebrate Its Staff During National Health IT Week 2014 2Health News:New Book Helps Millions of Children Deal With The Emotional Pains of Suffering From Eczema 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 3Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 3
... CHARLESTON, W.Va., Jan. 28 Author Ernie Vecchio ... Soul,s Intent" (published by iUniverse -- http://www.iuniverse.com ... experiences, findings, and insights while treating individuals recovering ... with trauma patients that when personality gets stripped ...
... diabetes, heart disease, developmental problems , , WEDNESDAY, Jan. 28 ... to harden plastics for consumer products such as baby ... body much longer than thought, a new study says. ... come from many different sources, not just food products, ...
... Security vendors gradually built a strong presence in ... the medical community. Technological advances and increasing applications ... staff coming to terms with inevitable compliance standards ... double-digit rates, the market looks highly lucrative over ...
... Foundation is,holding its Annual Fundraising Benefit this evening in ... Palace Hotel and serves as the showcase,for recent advances ... Benefit begins at 5 pm with a scientific overview ... of GRF,s Catalyst for a,Cure (CFC) consortium. A reception ...
... Jan. 28 The International Medical Interpreters Association ... structure for its organization. "Our revised bylaws do ... are unevenly distributed among different states and this ... Arocha, IMIA President.The organization will now have a ...
... REM Medical Corporation, a leader in innovative fatigue management ... Gordon Trucking, has chosen REM Medical as its provider ... will provide obstructive sleep apnea (OSA) diagnostic and treatment ... high probability of this serious sleep disorder. The ...
Cached Medicine News:Health News:'The Soul's Intent': An Interview with the Divine 2Health News:Controversial Chemical Lingers Longer in the Body: Study 2Health News:Controversial Chemical Lingers Longer in the Body: Study 3Health News:Frost & Sullivan Finds Compliance Requirements Drive the Healthcare Security Boom 2Health News:Frost & Sullivan Finds Compliance Requirements Drive the Healthcare Security Boom 3Health News:Glaucoma Research Foundation to Hold Annual Fundraising Benefit 2Health News:International Medical Interpreter Association Appoints IMIA State Representatives 2Health News:Gordon Trucking Begins Sleep Apnea Wellness Program with REM Medical Corporation 2
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
Medicine Products: